| Q41844732 | ALTernative Telomere Maintenance and Cancer. |
| Q64883763 | Administration of a Nucleoside Analog Promotes Cancer Cell Death in a Telomerase-Dependent Manner. |
| Q43262045 | Amarogentin Induces Apoptosis of Liver Cancer Cells via Upregulation of p53 and Downregulation of Human Telomerase Reverse Transcriptase in Mice |
| Q35441872 | Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer |
| Q27853042 | BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence |
| Q48677433 | Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma |
| Q33990112 | Crosstalk between telomere maintenance and radiation effects: A key player in the process of radiation-induced carcinogenesis. |
| Q35848234 | Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1. |
| Q27853057 | Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. |
| Q53596121 | Dose-dependent cytotoxic effects of boldine in HepG-2 cells-telomerase inhibition and apoptosis induction. |
| Q26766319 | Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms |
| Q54190292 | Frequency of TERT promoter mutations in primary tumors of the liver. |
| Q38890930 | Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease |
| Q28394370 | Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma |
| Q38151013 | G-quadruplex structures in the human genome as novel therapeutic targets. |
| Q51821033 | Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. |
| Q27852353 | Highly prevalent TERT promoter mutations in aggressive thyroid cancers |
| Q43128951 | Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma |
| Q33439918 | Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis |
| Q58705137 | Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells |
| Q26781538 | Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials |
| Q38737293 | Kallikrein-related peptidases (KLKs) and the hallmarks of cancer |
| Q64066644 | LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer |
| Q37671465 | Localization-dependent and -independent roles of SLX4 in regulating telomeres |
| Q39433499 | Loss of telomere protection: consequences and opportunities. |
| Q47702648 | Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms |
| Q38331666 | Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors |
| Q93088940 | Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications |
| Q90470130 | Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology |
| Q36776863 | Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex |
| Q52716634 | Pathways for maintenance of telomeres and common fragile sites during DNA replication stress. |
| Q48203042 | Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. |
| Q39036538 | Promoting active learning of graduate student by deep reading in biochemistry and microbiology pharmacy curriculum |
| Q64927273 | Real-time monitoring of DNA G-quadruplexes in living cells with a small-molecule fluorescent probe. |
| Q38370778 | Signaling pathways in HPV-associated cancers and therapeutic implications. |
| Q92495595 | Stilbene Compounds Inhibit Tumor Growth by the Induction of Cellular Senescence and the Inhibition of Telomerase Activity |
| Q38700449 | Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells |
| Q47991246 | TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma |
| Q38744769 | TERT Promoter Mutations in Thyroid Cancer |
| Q33682388 | TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer |
| Q54314475 | TERT promoter mutations in clear cell renal cell carcinoma. |
| Q92059913 | TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome |
| Q60917015 | Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma |
| Q28079188 | Telomerase as a Cancer Target. Development of New Molecules |
| Q38232447 | Telomerase promoter mutations in cancer: an emerging molecular biomarker? |
| Q26744808 | Telomere and Telomerase Therapeutics in Cancer |
| Q33613946 | Telomere biology and translational research. |
| Q34426966 | Telomere maintenance mechanisms in cancer: clinical implications |
| Q38655650 | The [Au(9-methylcaffein-8-ylidene)2]+ / DNA Tel23 System: Solution, Computational and Biological Studies. |
| Q37688898 | The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma |
| Q90339275 | The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer |